Cite
HARVARD Citation
McInnes, I. et al. (n.d.). P173 Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active PsA and inadequate response to non-biologic DMARDs (SELECT-PSA-1): a double-blind, randomised controlled phase III trial. Rheumatology. p. . [Online].